PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
7917798-0	1994	The pharmacokinetics, pharmacodynamics and comparative efficacy of flurbiprofen LAT.	Flurbiprofen	67-79	linker for activation of T cells	Homo sapiens	80-83	
9132322-12	1997	Of the patients receiving flurbiprofen LAT, 94% regarded it as a convenient form of treatment.	Flurbiprofen	26-38	linker for activation of T cells	Homo sapiens	39-42	
9132322-16	1997	In conclusion, local treatment of soft-tissue rheumatism with flurbiprofen LAT was demonstrably superior to benchmark oral therapy with diclofenac sodium over a 2-week period in terms of both efficacy and gastrointestinal tolerability.	Flurbiprofen	62-74	linker for activation of T cells	Homo sapiens	75-78	
9132322-17	1997	Flurbiprofen LAT provided both an effective and convenient form of topical SAID treatment.	Flurbiprofen	0-12	linker for activation of T cells	Homo sapiens	13-16	
9132322-6	1997	A statistically significant difference was observed in favour of flurbiprofen LAT for the principal measure, namely the investigator"s opinion of overall change in clinical condition: 49/53 (92%) patients treated with flurbiprofen LAT had improved by day 14 compared with 36/49 (73%) patients receiving diclofenac sodium (p = 0.03; eligible dataset).	Flurbiprofen	65-77	linker for activation of T cells	Homo sapiens	231-234	
9132322-6	1997	A statistically significant difference was observed in favour of flurbiprofen LAT for the principal measure, namely the investigator"s opinion of overall change in clinical condition: 49/53 (92%) patients treated with flurbiprofen LAT had improved by day 14 compared with 36/49 (73%) patients receiving diclofenac sodium (p = 0.03; eligible dataset).	Flurbiprofen	218-230	linker for activation of T cells	Homo sapiens	78-81	
9132322-6	1997	A statistically significant difference was observed in favour of flurbiprofen LAT for the principal measure, namely the investigator"s opinion of overall change in clinical condition: 49/53 (92%) patients treated with flurbiprofen LAT had improved by day 14 compared with 36/49 (73%) patients receiving diclofenac sodium (p = 0.03; eligible dataset).	Flurbiprofen	218-230	linker for activation of T cells	Homo sapiens	231-234	
7917798-3	1994	In localised soft-tissue rheumatism and osteoarthrosis of the knee joint, flurbiprofen LAT has been shown to be at least as efficacious as indomethacin ointment and comparable in efficacy to flurbiprofen 40 mg three times daily and ibuprofen 200 mg three times daily.	Flurbiprofen	74-86	linker for activation of T cells	Homo sapiens	87-90	
8220919-1	1993	The objective of the present study was to establish the efficacy and tolerability of local action transcutaneous flurbiprofen (flurbiprofen LAT) in the treatment of soft tissue lesions.	Flurbiprofen	113-125	linker for activation of T cells	Homo sapiens	140-143	
8220919-8	1993	Eight out of 53 (15%) patients receiving flurbiprofen LAT reported a total of 10 adverse events, compared with three out of 51 (6%) reporting seven events among controls.	Flurbiprofen	41-53	linker for activation of T cells	Homo sapiens	54-57	
8220919-10	1993	We conclude that flurbiprofen LAT is an effective and acceptable treatment for soft tissue lesions, and should be considered as an alternative therapy to local steroid injection.	Flurbiprofen	17-29	linker for activation of T cells	Homo sapiens	30-33